Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs
- PMID: 35042101
- PMCID: PMC9238179
- DOI: 10.1016/j.drugalcdep.2022.109265
Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs
Abstract
Background: Using data from a randomized trial, we evaluated the cost of HCV care facilitation that supports moving along the continuum of care for HIV/HCV co-infected individuals with substance use disorder.
Methods: Participants were HIV patients residing in the community, initially recruited from eight US hospital sites. They received HCV care facilitation (n = 51) or treatment as usual (n = 62) for up to six months. We used micro-costing methods to evaluate costs from the healthcare sector and patient perspectives in 2017 USD. We conducted sensitivity analyses varying care facilitator caseloads and examined offsetting savings using participant self-reported healthcare utilization.
Results: The average site start-up cost was $6320 (site range: $4320-$7000), primarily consisting of training. The mean weekly cost per participant was $20 (site range: $4-$30) for care facilitation visits and contacts, $360 (site range: $130- $700) for supervision and client outreach, and $70 (site range: $20-$180) for overhead. In sensitivity analyses applying a weekly caseload of 10 participants per care facilitator (versus 1-6 observed in the trial), the total mean weekly care facilitation cost from the healthcare sector perspective decreased to $110. Weekly participant time and travel costs averaged $7. There were no significant differences in other healthcare service costs between participants in the intervention and control arms.
Conclusion: Weekly HCV care facilitation costs were approximately $450 per participant, but approximately $110 at a real-world setting maximum caseload of 10 participants per week. No healthcare cost offsets were identified during the trial period, although future savings might result from successful HCV treatment.
Trial registration: ClinicalTrials.gov NCT01612169 NCT02641158.
Keywords: Care facilitation; Cost; HIV; Hepatitis C; Substance use disorder.
Copyright © 2022 Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of Interest
All authors declare that they have no conflict of interest.
Figures

References
-
- Agency for Healthcare Research and Quality, 2018. Medical Expenditure Panel Survey. https://meps.ahrq.gov/mepsweb/. (Accessed February 13 2019). - PubMed
-
- American Association for the Study of Liver Diseases & Infectious Diseases Society of America, 2019. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. https://www.hcvguidelines.org/. (Accessed March 14 2018).
-
- Centers for Medicare & Medicaid Services, 2017. Physician Fee Schedule Search. https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. (Accessed April 1, 2019.
Publication types
MeSH terms
Associated data
Grants and funding
- UG1 DA020024/DA/NIDA NIH HHS/United States
- P30 AI050409/AI/NIAID NIH HHS/United States
- UG1 DA013034/DA/NIDA NIH HHS/United States
- UG1 DA015815/DA/NIDA NIH HHS/United States
- UM1 TR004538/TR/NCATS NIH HHS/United States
- P30 DA040500/DA/NIDA NIH HHS/United States
- P30 DA011041/DA/NIDA NIH HHS/United States
- U10 DA020024/DA/NIDA NIH HHS/United States
- T32 NR014205/NR/NINR NIH HHS/United States
- U10 DA015815/DA/NIDA NIH HHS/United States
- U10 DA013720/DA/NIDA NIH HHS/United States
- L30 NR018771/NR/NINR NIH HHS/United States
- UG1 DA013720/DA/NIDA NIH HHS/United States
- P30 AI073961/AI/NIAID NIH HHS/United States
- UG1 DA015831/DA/NIDA NIH HHS/United States
- UG1 DA013035/DA/NIDA NIH HHS/United States
- HHSN271201400028C/DA/NIDA NIH HHS/United States
- K01 DA051348/DA/NIDA NIH HHS/United States
- T32 DA031099/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical